Loading
A phase 2 trial of Inavolisib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer is a phase 2 interventional study registered as NCT07368998 by Hoffmann-La Roche, with 80 participants planned, started 2026-02-18 and due to reach its primary completion in 2028-10-31. Interventions recorded: Inavolisib and Fulvestrant.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Fulvestrant and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.